Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-Ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine‑5‑carboxamide is an experimental small molecule belonging to the pyrazolopyridine class of organic compounds. It has a molecular formula of C21H25N5O2 and a molecular weight of approximately 379.46 g/mol. The compound is not approved for clinical use in any country and has no reported indications or completed clinical trials as of now. Its mechanism of action and therapeutic targets have not been described in public databases or literature to date. The compound appears primarily in chemical and drug discovery databases as a research substance with no known developer or manufacturer associated with pharmaceutical development.[1][2][3][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide.